All News

Slim,waist,obese,obesity

Together PSO Trial - Combination Ixekizumab and Tirzepatide

Jack Cush, MD

Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over IXE alone.

Read Article
pregnancy,embryo,fetal

Can I Use JAK Inhibitors During Pregnancy?

Jack Cush, MD

In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy."

Read Article
Terkeltaub RNL26 Gout lecture

Disease Modification, Disparities and the Next Therapeutic Frontier in Gout

Audrey Gibson, PA-C

Gout management has entered what Dr. Robert Terkeltaub MD from UC San Diego described as its “disease-modifying era,” during his talk at RheumNow Live 2026. In a recent comprehensive review of the past, present, and future of gout therapy, the central message was clear: “We can really apply disease modification to gout based on prospective, randomized controlled trials.”

Read Article
RheumNow Podcast square

Maui Potpourri (2.13.2026)

Jack Cush, MD

Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.

Read Article
RheumNow Podcast square

ANA Pollution (2.06.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

Read Article
Comorbidity & Health Management https://t.co/cSwCEDKL28 https://t.co/WP7yIdWPVY

Links:

Dr. John Cush RheumNow ( View Tweet)
Maui Potpourri (2.13.2026) Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow Live 2026. https://t.co/ieRhIVZb2D https://t.co/KaYtSnHUIL

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC Given rising resistance, effective first-line regimens and adequate duration (14 days) are critical. PPI-based quadruple regimens remain highly effective when patients can adhere. #RNL26 https://t.co/rQps2rls8G
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC Who should be tested? Test only if you plan to treat. Indications include: • Active or prior ulcers • MALT lymphoma • Gastric cancer • Chronic atrophic gastritis Avoid indiscriminate testing. #RNL26 atoid arthritis https://t.co/2KJluSAPNx
Dr. John Cush RheumNow ( View Tweet)
RNL 26 Report: Spondyloarthritis Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session. https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity, Surgery, and Optimizing Patient Care Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC Arthur Kavanaugh’s RheumNow 2026: Why Do Plain X-Rays in Psoriatic Arthritis? Thought-provoking session on the role of plain radiographs in psoriatic arthritis—not as relics of the past, but as tools that still inform prognosis, function, and long-term

Dr. John Cush RheumNow ( View Tweet)

RT @Gibson_RheumPAC A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD #RNL26 Placebo in Rheumatology - STEP talk Kerschbaumer What plays role in PBO? Treatment adherence effect w better background therapy - may appear to be PBO Impact in globalization of recruitment patterns, affects background PBO Education of pts bridges gap

Dr. John Cush RheumNow ( View Tweet)

We are Doctors, Not Providers! With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians (ACP) is concerned about the use of the term provider to describe physicians. https://t.co/Vf6Wx0w28d https://t.co/RXTTFq34Rj

Links:

Dr. John Cush RheumNow ( View Tweet)
Staying Ahead of Spondyloarthritis The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis." https://t.co/hZeqYC7wi3 https://t.co/2eKEueAukY

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Fleischman on lupus dz activity including SLEDAI, which you can use on practice. But not for practice are SLE-DAS, BILAG, BICLA, SRI-4, DORIS @RWCSmtg #RWCS26 https://t.co/7sOaE7SMht
Dr. John Cush RheumNow ( View Tweet)
Rheum Cases & Guidelines https://t.co/0zI2KRuwxa https://t.co/TBw12LFh6i

Links:

Dr. John Cush RheumNow ( View Tweet)
ANA Pollution (2.06.2026 Dr. Jack Cush reviews the news, journal articles, and regulatory news from this past week on RheumNow. https://t.co/cfEjEr36Tb https://t.co/OJbE6P3k6p

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Recent Government Funding The American College of Rheumatology (ACR) praised the recent Congressional CY 26 funding package, highlighting its provisions to extend Medicare telehealth payment flexibilities, enhance transparency in pharmacy benefit management, and https://t.co/gr3X7RRGLN
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×